25 September, 2020
The regulatory approval and commercialisation of Luxturna in 2017 has opened the floodgates for gene therapy, with numerous clinical trials underway or rapidly approaching. Dr Tom Edwards and Dr Lauren Ayton will update Retina Australia members on the national approach to identifying and characterising people who might be eligible for these trials (through the Inherited Retinal Disease Natural History Study), as well as describing the most promising developments in the field.
This webinar will take place on Saturday 17th October at 2:00pm EST. You can find a copy of the flyer in Word version here or in PDF version here
https://retinaaustralia.com.au/webinar-event-gene-therapy-clinical-trials-and-new-developments-in-ird-research/
Other News
New Board Appointments
Retina Australia directors are thrilled to announce the recent appointment of Associate Professor Anai Gonzelez-Cordero and Dr Alexis (Ceecee) Britten-Jones to the Board. Anai and Ceecee have been long...
First treatment for geographic atrophy approved in Australia
Apellis' SYFOVRE® (pegcetacoplan) TGA Approved Apellis Pharmaceuticals, Inc. announced today that Australia’s Therapeutic Goods Administration...
2025 Research Grants awarded
Retina Australia is delighted to announce two new Research Grants awarded for 2025. Both grant projects will be focusing on the discovery of potential new...